DrugPatentWatch Database Preview

Details for Patent: 9,023,893

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,023,893 protect, and when does it expire?

Patent 9,023,893 protects TEKTURNA HCT and is included in one NDA.

This patent has ninety-three patent family members in thirty-one countries.

Summary for Patent: 9,023,893

Title:	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
Abstract:	The invention relates to a combination comprising the renin inhibitor of formula (I) ##STR00001## or a pharmaceutically acceptable salt thereof.
Inventor(s):	Hewitt; William (Pottstown, PA), Vasella; Daniel L (Basel, CH), Webb; Randy L (Flemington, NJ)
Assignee:	Novartis AG (Basel, CH)
Application Number:	13/235,659
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent 9,023,893

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Noden Pharma	TEKTURNA HCT	aliskiren hemifumarate; hydrochlorothiazide	TABLET;ORAL	022107-001	Jan 18, 2008		DISCN	Yes	No			Y
Noden Pharma	TEKTURNA HCT	aliskiren hemifumarate; hydrochlorothiazide	TABLET;ORAL	022107-002	Jan 18, 2008		DISCN	Yes	No			Y
Noden Pharma	TEKTURNA HCT	aliskiren hemifumarate; hydrochlorothiazide	TABLET;ORAL	022107-003	Jan 18, 2008		RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 9,023,893

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0028151.9	Nov 17, 2000

International Family Members for US Patent 9,023,893

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	317692
Austria	397445
Australia	2002223680